Chronic Myeloid Leukemia Coverage from Every Angle

Neil P. Shah, MD, PhD, on Chronic Myeloid Leukemia: When Can TKI Therapy Be Stopped?

Posted: Friday, March 22, 2019

Neil P. Shah, MD, PhD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses which patients with CML may be considered for discontinuation of tyrosine kinase inhibitor therapy, when treatment should be stopped, and when it may be restarted.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.